clinical trial · NCT01093326
Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis
Actelion·phase2·completed·n = 353
Multiple SclerosisPonesimod 10 mgPonesimod 20 mgPonesimod 40 mg
brief summary
This study is an extension to the study AC-058B201 and will investigate the long-term safety, tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis.
started
May 12, 2010
primary completion
Sep 6, 2023
completion
Sep 6, 2023
last updated
Mar 30, 2025
official title
Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of Three Doses of Ponesimod, an Oral S1P1 Receptor Agonist, in Patients With Relapsing-remitting Multiple Sclerosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol